Alcohol-induced severe acute pancreatitis followed by hemolytic uremic syndrome managed with continuous renal replacement therapy

BMC Nephrology

Hai-yang Wu¹  Xin Li¹  Chun-hua Wang¹  Ai-hong Yuan¹  Peng Fu¹ 

[1] Department of Nephrology, Tongji Hospital, Tongji University, Alley 578, Xiangyin Road, Wujiaochang Town, 200433 Shanghai, China

关键词: Hemolytic-uremic syndrome;    Continuous renal replacement therapy;    Acute renal failure;    Acute pancreatitis;   

Others  :  1082757
DOI  :  10.1186/1471-2369-15-1

 received in 2013-04-17, accepted in 2013-12-27,  发布年份 2014

【 摘 要 】

Background

Acute kidney injury in patients with acute pancreatitis carries a poor prognosis. Hemolytic uremic syndrome (HUS) is characterized by non-immune hemolytic anemia, thrombocytopenia, and renal failure caused by platelet thrombi in the microcirculation of the kidney, and though rare in adults it is associated with high mortality and a high rate of chronic renal failure.

Case presentation

Herein, we report a case of alcohol-induced acute pancreatitis in a 38-year-old Chinese female complicated by HUS. Her renal function progressively deteriorated in 2 days, and daily continuous renal replacement therapy (CRRT) was thus performed for a total of 13 treatments. She also received intermittent transfusions of fresh frozen plasma. Her renal failure was successfully managed, with subsequent return of normal renal function. She was discharged 1 month after admission and follow-up at 3 months revealed normal urea and creatinine.

Conclusion

CRRT was shown to be useful for the treatment of HUS following acute pancreatitis. Prior case reports and our case should remind clinicians that HUS is a possible complication of acute pancreatitis. This study highlights the importance of early diagnosis and prompt initiation of CRRT to prevent mortality and improve outcomes.

【 授权许可】

   
2014 Fu et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Swisher KK, Doan JT, Vesely SK, Kwaan HC, Kim B, Lämmle B, Kremer Hovinga JA, George JN: Pancreatitis preceding acute episodes of thrombotic thrombocytopenic purpura-hemalytic uremic syndrome: report of five patients with a systematic review of published reports. Haematologica 2007, 92(7):936-943.
• [2]Tostivint I, Mougenot B, Flahault A, Vigneau C, Costa MA, Haymann JP, Sraer JD, Rondeau E: Adult haemolytic and uraemic syndrome: causes and prognostic factors in the last decade. Nephrol Dial Transplant 2002, 17(7):1228-1234.
• [3]Remuzzi G: Hemolytic uremic syndrome: past and present. Am J Kidney Dis 2000, 36(5):LIV-VI.
• [4]Silva VA: Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome secondary to pancreatitis. Am J Hematol 1995, 50(1):53-56.
• [5]Daryanani S, Wilde JT: Relapsing thrombotic thrombocytopenic purpura in association with recurrent pancreatitis. Clin Lab Haematol 1998, 20(5):317-318.
• [6]Bernardo A, Ball C, Nolasco L, Moake J, Dong JF: Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultra-large von Willebrand factor multimers under flow. Blood 2004, 104(1):100-106.
• [7]Chang JC, Kathula SK: Various clinical manifestations in patients with thrombotic microangiopathy. J Investig Med 2002, 50(3):201-206.
• [8]Gourley BL, Mesa H, Gupta P: Rapid and complete resolution of chemotherapy-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) with rituximab. Cancer Chemother Pharmacol 2010, 65(5):1001-1004.
• [9]Caramazza D, Quintini G, Abbene I, Malato A, Saccullo G, Lo Coco L, Di Trapani R, Palazzolo R, Barone R, Mazzola G, Rizzo S, Ragonese P, Aridon P, Abbadessa V, Siragusa S: Relapsing or refractory idiopathic thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the role of rituximab. Transfusion 2010, 50(12):2753-2760.
• [10]Prowle JR, Bellomo R: Continuous renal replacement therapy: recent advances and future research. Nat Rev Nephrol 2010, 6(9):521-529.